Zoetis(US:ZTS) Financial Modeling Prep·2025-11-04 02:00Core Insights - Zoetis Inc. is a leading global animal health company set to release its Q3 2025 earnings on November 4, 2025, with Wall Street anticipating EPS of $1.62 and revenue of approximately $2.41 billion [1][2] Financial Performance - The company is expected to surpass earnings estimates due to strong demand for companion animal products like Simparica Trio and Apoquel, indicating robust performance in this segment [2][6] - A year-over-year increase in earnings is projected, attributed to higher revenues for the quarter ending September 2025, which could positively impact stock price [3][6] Financial Metrics - Zoetis has a price-to-earnings (P/E) ratio of 24.60, indicating investors are willing to pay $24.60 for every dollar of earnings [4][6] - The price-to-sales ratio is 6.82, and the enterprise value to sales ratio is 7.39, reflecting the market's valuation of its revenue and sales [4] - The company maintains a debt-to-equity ratio of 1.36, suggesting a balanced use of debt and equity in financing, and a current ratio of 1.76 indicates it can comfortably cover short-term liabilities [5][6] - An earnings yield of 4.07% showcases the company's profitability based on earnings [5]